Pharma BD Deal Intelligence
Mylan's $550M cash buy of Bioniche gave it a durable North American injectables beachhead—the Galway plant still runs today—but the deal never disclosed standalone ROI and was quickly overshadowed by the much larger, more troubled $1.6B Agila acquisition three years later.
GEN framed the deal as Mylan's entry into US hospital injectables with immediate critical mass; Coury called it 'a complementary, high growth, high margin…
Bioniche Pharma had approximately $130 million in net revenue for the twelve months ended May 31, 2010, with a robust pipeline including 15 ANDAs pending FDA…
Mylan completed acquisition of Bioniche Pharma sooner than expected, establishing Mylan Institutional with a diverse hospital-setting portfolio across…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Mylan to acquire Ireland-based Bioniche Pharma for $550M cash, immediate North American hospital injectables presence. Closed September 2010.
Assessment window: 5yr post-close.
Hospital injectables span sterile small-molecule and biologic drug products administered IV/IM/SC in inpatient settings — including cytotoxic oncology agents, anesthetics, anticoagulants, and urology agents. Manufacturing is high-complexity (sterility, lyophilization, controlled substances) and FDA scrutiny is intense, creating durable barriers and limited-competition margins.
The 2010 US generic-injectables market was dominated by Hospira (subsequently acquired by Pfizer in 2015), Hikma/West-Ward, Sandoz, Sagent, and Teva-Parenteral, with APP Pharmaceuticals (acquired by Fresenius Kabi in 2008) controlling a large share of oncology generics. Mylan was sub-scale in injectables and used Bioniche to enter the segment with ~30 marketed products spanning analgesics/anesthetics, orthopedics, oncology, and urology, plus 15 pending ANDAs and 25+ pipeline products. The deal also let Mylan combine Bioniche with its UDL Laboratories unit-dose business to launch Mylan Institutional, targeting GPOs, hospitals, and long-term-care channels. CEO Robert Coury called injectables a 'complementary, high-growth, high-margin' segment with focus on 'difficult-to-develop and -manufacture compositions.' At a ~4.2x trailing-revenue multiple ($550M / $130M LTM), the deal was modestly priced versus the 5-7x range typical of injectables specialty deals at the time, with year-one accretion projected even before synergies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Inc. / Bioniche Pharma Holdings Limited (this deal) | 2010 | $550M | 60 |
| Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program) | 2015 | $265M | 61 |
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) | 2015 | $800M | 56 |
| Mylan Inc. / Agila Specialties (Strides Arcolab) | 2013 | $1.8B | 45 |
| Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business) | 2014 | $5.3B | 33 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
← Browse all deals · How we score deals
More: 2010 deals · Mylan Inc. deals · Oncology deals